Early
1 known investors
Early develops a home urinalysis system that pairs a clinical-grade electrochemical reader with disposable urine tests to screen for markers of serious conditions such as urinary tract cancers, diabetes, kidney disease, and heart disease risk, plus wellness markers, delivering results to an app in under five minutes. The consumer product is aimed at at-home early disease detection and is planned to launch in Spring 2027.
Founders & leadership
ME
Mark EmbertonChief Medical Officer